首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Tafa1 |
| Uniprot No | Q7TPG8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-133aa |
| 氨基酸序列 | MLLCHGSLQHTFQQHHLHRPEGGTCEVIAAHRCCNKNRIEERSQTVKCSCLPGKVAGTTRNRPSCVDASIVIGKWWCEMEPCLEGEECKTLPDNSGWMCATGNKIKTTRIHPRT |
| 预测分子量 | 20.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TAFA1重组蛋白的3篇参考文献(示例为模拟内容，实际文献需根据数据库查询)：
---
1. **文献名称**：*"Recombinant TAFA1 promotes neuronal survival and attenuates neuroinflammation in vitro"*
**作者**：Smith A, et al.
**摘要**：研究利用大肠杆菌系统表达TAFA1重组蛋白，证实其通过激活MAPK信号通路促进神经元存活，并抑制小胶质细胞炎症因子释放，提示其在神经退行性疾病中的潜在治疗价值。
2. **文献名称**：*"Structural characterization and functional analysis of TAFA1 as a chemokine-like protein"*
**作者**：Zhang L, et al.
**摘要**：通过X射线晶体学解析TAFA1重组蛋白的三维结构，发现其具有独特的折叠模式，体外实验显示其可趋化单核细胞迁移，可能与免疫调节功能相关。
3. **文献名称**：*"TAFA1 recombinant protein alleviates cognitive deficits in a mouse model of Alzheimer’s disease"*
**作者**：Wang Y, et al.
**摘要**：在阿尔茨海默病模型中，脑内注射TAFA1重组蛋白显著减少β-淀粉样斑块沉积，改善小鼠认知功能，机制可能与调节突触可塑性蛋白表达有关。
---
注：实际引用时请通过PubMed、Web of Science等平台检索真实文献，并核对作者与摘要准确性。
TAFA1. a member of the TAFA protein family, is a secreted chemokine-like protein encoded by the *TAFA1* gene in humans. This family, consisting of five members (TAFA1-5), shares structural homology with macrophage inhibitory factor (MIF) but exhibits distinct expression patterns and functions. TAFA1 is predominantly expressed in the brain, particularly in the hippocampus, amygdala, and cortical regions, suggesting a role in neurodevelopment and synaptic plasticity. It contains a conserved N-terminal domain and a C-terminal domain with predicted cytokine-like activity, enabling interactions with cell surface receptors to modulate intracellular signaling.
Research indicates TAFA1 regulates neurite outgrowth, neuronal survival, and synaptic connectivity, potentially through interactions with receptors like CCR5 or CXCR4. Its dysregulation has been implicated in neuropsychiatric disorders, including autism spectrum disorder (ASD) and schizophrenia, as well as neurodegenerative conditions like Alzheimer’s disease. For instance, altered TAFA1 levels correlate with synaptic dysfunction and amyloid-beta pathology in Alzheimer’s models.
Recombinant TAFA1 protein is engineered using expression systems like *E. coli* or mammalian cells to study its biochemical properties and therapeutic potential. Challenges include maintaining proper folding and post-translational modifications critical for its bioactivity. Current applications span in vitro neuronal culture studies, animal models of neurodegeneration, and drug screening platforms. As a neurotrophic factor, TAFA1 holds promise for therapies targeting neural repair or neuroinflammation, though its precise mechanisms and receptor interactions require further elucidation. Advances in recombinant protein technology may accelerate its translation into clinical research.
×
